Skip to main content
. 2011 May 18;6(5):e19665. doi: 10.1371/journal.pone.0019665

Figure 5. Circulating 125I following both IP and vaginal application.

Figure 5

A. Circulating 125I in the 120 h following IP injection. B. Circulating 125I in the 120 h following vaginal application. •, 125I-PEGLA non-mated; ▪, 125I-PEGLA mated; ◊, 125I-PEGBSA non-mated. *, significant difference (P<0.05) to ◊.